Dexcom announces new wearable device for managing type 2 diabetes without insulin

Continuous glucose monitor maker Dexcom is developing a type 2 diabetes monitor for people who don’t need insulin, with a 15-day sensor and a cash-payment option for patients not covered by Medicare and health insurers , who want daily judgment. Help.

With the number of Americans affected by diabetes exceeding 37 million, according to the US Centers for Disease Control, health care technology developers and researchers are seeking to enhance diabetes prevention, early detection, management and care.

According to a report last week, Dexcom Chief Executive Kevin Sayer said, “There are three major decisions that a person with type 2 diabetes who is not taking insulin makes.” San Diego Union-Tribune.

“Those decisions are exercise, food and medications.”

Sayers reportedly told attendees at an American Diabetes Conference in San Diego that the company’s new sensor — which is about a year or so from launch to market — could help millions of patients manage type 2 diabetes without insulin. will help, and it will help millions of pre-diabetics. Patients learn how their daily habits affect their conditions.

According to researchers at the University of Utah Health, the Regenstreif Institute and Hitachi, while 10% of adults worldwide have been diagnosed with type 2 diabetes mellitus, it is a small percentage for whom it is difficult to control blood glucose levels and avoid serious complications. Many medicines are needed to survive. Use of artificial intelligence to analyze electronic health record data for T2DM characteristics.

“With this system, they can see their meal plan. They can watch their exercise. They can look at any medication they take – whether it’s diabetes medication or medication for other conditions,” Sayers said of the new wearable medical device Dexcom developed and reviewed by the US government .

He said that in general, wearable glucose monitors should show how they can help reduce costs across the entire health care system.

“One-quarter of the dollars that are spent on health care in the US are spent on diabetes,” he said.

“The only way to change these trends is to give people information that can improve their health.”

Dexcom also announced Tuesday that its G7 CGM, which has a predictive immediate low-alert feature in addition to real-time alerts for those using insulin to manage diabetes, has received market approval from Health Canada. Got it.

The CGM device received US market approval in December. In January, Sayers reported mobihealthnews With the emergence of the new G7 platform, Dexcom CGMs have become “interoperable and connectable” with greater cyber security.

Andrea Fox is a senior editor for Healthcare IT News.
Email: afox@himss.org
Healthcare IT News is a HIMSS Media publication.